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For patients with acute myocardial infarction (MI), the immediate therapeutic goal is to es-
tablish the patency of the infarct-related artery. Prolonged myocardial ischemia, however, of-
ten breaks down the coronary microvasculature, and the flow to the infarct myocardium may be
markedly reduced. This is called the no-reflow phenomenon. This phenomenon is important not
solely because it correlates with infarct size but because it provides additional prognostic informa-
tion. With recent advances in imaging modalities, the no-reflow phenomenon is observed more fre-
quently than when clinical judgment alone is used. Patients with this phenomenon are associated
with poor functional and clinical outcomes. Now, the no-reflow phenomenon can be a parameter
with which to predict high-risk patients. The focus of reperfusion therapy has shifted toward the
improvement of myocardial perfusion. The improvement of myocardial perfusion could promote
the functional recovery of viable muscle and reduce infarct expansion, which is associated with
favorable clinical outcomes. For this purpose, pharmacological interventions and catheter-based
devices to retrieve embolic materials have been proposed. Advances in our understanding of the
pathophysiology of microvascular dysfunction would aid the development of therapeutic strategies
for its prevention and treatment.
KEYWORDS: cardiac function, coronary intervention, microcirculation, myocardial infarction,
reperfusion
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For patients with acute myocardial infarction (MI),  the immediate therapeutic goal is to establish the 
patency of the infarct-related artery.  Prolonged myocardial ischemia,  however,  often breaks down 
the coronary microvasculature,  and the ﬂow to the infarct myocardium may be markedly reduced.  
This is called the no-reﬂow phenomenon.  This phenomenon is important not solely because it corre-
lates with infarct size but because it provides additional prognostic information.  With recent advances 
in imaging modalities,  the no-reﬂow phenomenon is observed more frequently than when clinical judg-
ment alone is used.  Patients with this phenomenon are associated with poor functional and clinical 
outcomes.  Now,  the no-reﬂow phenomenon can be a parameter with which to predict high-risk 
patients.  The focus of reperfusion therapy has shifted toward the improvement of myocardial perfu-
sion.  The improvement of myocardial perfusion could promote the functional recovery of viable 
muscle and reduce infarct expansion,  which is associated with favorable clinical outcomes.  For this 
purpose,  pharmacological interventions and catheter-based devices to retrieve embolic materials have 
been proposed.  Advances in our understanding of the pathophysiology of microvascular dysfunction 
would aid the development of therapeutic strategies for its prevention and treatment.
Key words: cardiac function,  coronary intervention,  microcirculation,  myocardial infarction,  reperfusion 
fter acute myocardial infarction (MI),  the 
immediate therapeutic goal is to establish the 
patency of the infarct-related artery.  The successful 
restoration of epicardial coronary artery patency,  
however,  does not necessarily translate into improved 
tissue perfusion.  In the so-called no-reﬂow phenome-
non,  coronary microvasculature is often disruptied 
structurally,  signiﬁcantly reducing the ﬂow to the 
previously ischemic myocardium.  If this phenomenon 
occurs before or because of the percutaneous coronary 
intervention (PCI) procedure,  coronary ﬂow is sig-
niﬁcantly reduced.  With the advancement of imaging 
modalities,  the percentage of patients in whom micro-
vascular obstruction is detected has increased com-
pared to the percentage detected by clinical judgment 
alone.
　 Patients with the no-reﬂow phenomenon have a 
poor clinical prognosis [1].  Therefore,  our attention 
has shifted from just epicardial artery patency to the 
status of the coronary microvasculature.  A better 
understanding of the pathophysiology of the no-reﬂow 
phenomenon in acute MI patients could aid the devel-
opment of preventive and therapeutic strategies.  In 
this review,  I attempt to provide an in-depth under-
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standing of the no-reﬂow phenomenon from the bench 
to the bedside.
Pathophysiology of the No-reﬂow 
Phenomenon
　 The no-reﬂow phenomenon in the myocardium was 
originally described in 1974 by Kloner et al.  [2].  The 
capillary structure is completely destroyed in the no-
reﬂow zone as a result of endothelial swelling,  com-
pression by tissue,  myocyte edema,  and neutrophil 
inﬁltration.   This pathologicprocess can be acceler-
ated by coronary reperfusion [3].  Coronary reperfu-
sion promotes several mechanisms,  involved in this 
process,  including tissue edema,  endothelial disrup-
tion,  plugging of capillaries by neutrophils and micro-
thrombi,  inﬂammation due to the generation of oxy-
gen-free radicals and the activation of complements,  
and contracture of neighboring myocytes (Fig.  1).  
Thus,  the no-reﬂow phenomenon results partly from 
reperfusion injury.  In patients with acute MI,  PCI 
potentially accelerates this pathological process.  
Mechanical stress to the coronary arterial plaque may 
accelerate the liberation of microthromboemboli and 
plaque gruel particles,  which are thought to be show-
ered downstream,  thus obstructing small arteries and 
arterioles,  which in turn increases coronary arterial 
resistance and causes small MI.
　 The factors related to the development of the no-
reﬂow phenomenon vary based on whether the cause is 
capillary destruction or microemboli to small arteries.  
Factors related to capillary destruction are similar to 
those of myocardial necrosis after acute MI,  such as 
the duration of coronary occlusion,  the extent of 
infarct risk area,  the patency of the infarct-related 
artery,  the development of collateral circulation,  and 
the presence or absence of pre-infarction angina [4].  
Pre-infarction angina produces a preconditioning-like 
eﬀect and may promote collateral development.  The 
quality of collateral channels is important for main-
taining microvascular integrity.  
　 Microemboli are likely to be generated during PCI 
to lipid-rich vulnerable plaques.  The liberation of 
plaque components,  including platelet-ﬁbrin complex,  
macrophages,  and cholesterol crystals,  could obstruct 
resistance arteries and provoke arteriole spasms,  
leading to microvascular congestion.  Coronary angiog-
raphy shows sluggish coronary ﬂow,  but the reduction 
in coronary blood ﬂow is usually transient [5,  6].  We 
can detect and quantify embolic particles in patients.  


















Fig. 1　 Mechanisms of the no-reﬂow phenomenon in acute myocardial infarction.
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Okamura et al.  [7] used a Doppler guidewire to detect 
high-intensity transient signals,  which allowed them to 
count the number of embolic particles.  The average 
number of embolic particles was 20ﾝ30 throughout the 
PCI procedure in patients with acute MI.  If the num-
ber of embolic particles is within this range,  any 
notable derangement of coronary microcirculation is 
unlikely.  Embolic particles can provoke myocardial 
damage and reduce myocardial blood ﬂow only if they 
are large (＞200µm diameter) or their numbers are 
huge.
Diagnosis of the No-reﬂow Phenomenon
　 Myocardial contrast echocardiography.
Myocardial contrast echocardiography (MCE) uses 
intravascular contrast agents that contain microbub-
bles as blood tracers.  This modality can assess 
microvascular perfusion (Fig.  1),  and hence has 
become the gold standard for investigating the no-
reﬂow phenomenon.   Initially,  we performed MCE 
during coronary angiography by injecting sonicated 
microbubbles into recanalized infarct-related arteries. 
Contrast perfusion defects of substantial size,  imply-
ing the presence of no-reﬂow zones,  were seen in 25ﾝ
30ｵ of patients with acute MI,  even though coronary 
angiography showed open arteries (Fig.  2) [8].  At 
present, we can perform MCE at the bedside with 
intravenous injection of commercially available con-
trast agents (Fig.  3).  The contrast perfusion defects 
appear in the center of the infarct zone,  and may lead 
to the underestimation of the ultimate infarct size.  
They can match the infarct size after the vasodilator 
stress.  
　 We can quantify the microvascular damage by 
measuring regional myocardial blood volume fraction.  
Since 90ｵ of myocardial blood volume exists in cap-
illaries,  myocardial blood volume reﬂects capillary 
integrity as well as myocardial viability.  The back-
ground-subtracted acoustic intensity for the myocar-
dium correlates with the number of microbubbles.  
When the intensity is normalized to acoustic intensity 
for the adjacent left ventricular cavity,  myocardial 
blood volume fraction can be measured.  We developed 
163No-reﬂow Phenomenon in Acute MIJune 2009
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Fig. 2　 Myocardial contrast echocardiograms in patients with acute anterior wall myocardial infarction: good reﬂow and no reﬂow. 
Both patients had total occlusion in the proximal left anterior descending coronary artery.  After percutaneous coronary intervention,  both 
patients had patent coronary artery.  We injected sonicated contrast medium into the left coronary artery.  In the case on the left,  all of the 
myocardium shows contrast enhancement,  implying the success of coronary reperfusion at the myocardium level.  In the right case,  sub-
stantially sized contrast perfusion defects were observed in the distal septum and in the cardiac apex (arrows),  implying the occurrence of 
the no-reﬂow phenomenon.
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software to show the distribution of myocardial blood 
volume of the left ventricle in a colour-coded fashion.  
One MCE image provides enough data for the analysis,  
and shows the map of capillary integrity of the left 
ventricle [9].
　 Coronary angiography. Microvascular dys-
function reduces coronary blood ﬂow,  and appears on 
coronary angiography as sluggish coronary.  Throm-
bolysis In Myocardial Infarction (TIMI) blood ﬂow 
grades are used to evaluate the quality of coronary 
ﬂow [10].  This method measures the coronary artery 
clearance of radiographic dye.  Historically,  TIMI-0/1 
ﬂow was considered a failure of reperfusion and TIMI-
2/3 ﬂow indicates successful reperfusion.  In practice,  
however,  TIMI-2 ﬂow is associated with poor clinical 
outcomes,  similar to the outcomes for patients with 
TIMI-0/1 ﬂow [11].  Our study using MCE indicated 
that TIMI-2 ﬂow is associated with substantial no-
reﬂow phenomenon; therefore,  only TIMI-3 ﬂow 
indicates reperfusion success [12].  Even after stent-
ing,  patients with acute MI do not necessarily achieve 
TIMI-3 ﬂow; this underscores the fact that the major 
cause of sluggish ﬂow is unrelated to the degree of 
epicardial stenosis but rather is related to decreased 
perfusion in the microvasculature.
　 Doppler assessment of coronary blood ﬂow 
velocity pattern (Fig. 4). We can monitor coro-
nary blood ﬂow velocity with a Doppler guidewire and 
transthoracic Doppler technique.  The no-reﬂow phe-
nomenon has a characteristic coronary blood ﬂow 
pattern,  with 3 main components: systolic ﬂow 
reversal; reduced antegrade systolic ﬂow; and for-
ward diastolic ﬂow with a rapid deceleration slope 
[13].  Because of this to-and-fro nature,  coronary 
forward ﬂow is reduced.  The coronary blood ﬂow 
velocity pattern is caused by extensive capillary dam-
age,  which is associated with increased capillary 
resistance and a reduced myocardial blood pool.  The 
coronary blood ﬂow velocity pattern diﬀers in indi-
viduals with microemboli from those without,  and is 
characterized with slow forward ﬂow and an increase 
in the diastolic-to-systolic ﬂow ratio,  indicating 
increased coronary arterial resistance.  At least 2 
diﬀerent coronary blood ﬂow velocity patterns can,  
therefore,  be seen in patients with slow coronary ﬂow 
after PCI.
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Normal case Anterior MI
Fig. 3　 Myocardial contrast echocardiograms in a normal case and in a patient with anterior myocardial infarction.
We can perform myocardial contrast echocardiography with intravenous injection of commercially available contrast medium.  In the normal 
subject,  all of the left ventricular myocardium shows contrast enhancement.  In the case of anterior myocardial infarction (MI),  contrast 
perfusion defects were observed from the distal septum to the cardiac apex (arrows).  
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Clinical Implications of the No-reﬂow 
 Phenomenon
　 The no-reﬂow phenomenon is important not solely 
because it correlates with infarct size but also because 
it provides additional prognostic information [14].  
Because the no-reﬂow phenomenon occurs after the 
myocytes in the area are already dead,  the presence 
of the no-reﬂow zone virtually rules out later recovery 
of function.  A large no-reﬂow zone is associated with 
reduced left ventricular contractile function.  In addi-
tion to predicting the recovery of systolic function,  
the presence of no-reﬂow predicts acute complications 
after acute MI.  Patients with the no-reﬂow phenome-
non are in the highest-risk subgroup of patients 
undergoing reperfusion,  with increased associated 
risks of early and more protracted congestive heart 
failure,  and of death.  A large no-reﬂow zone may 
impede the infarct's ability to heal and prevent deliv-
ery of pharamacological agents into the infarct zone.  
No-reﬂow zones sustain transmural damage,  and in 
large zones infarct expansion and early left ventricular 
dilation are likely to occur.  The no-reﬂow phenome-
non was also linked to ventricular arrhythmias and 
even cardiac rupture.  There is also evidence that it 
may have an adverse eﬀect on left ventricular remod-
eling after MI.  This elevated risk has implications for 
therapy.
Treatment of the No-reﬂow Phenomenon
　 The focus of reperfusion therapy is shifting toward 
improving the patency of the wider vasculature in the 
aﬀected area rather than merely that of the target 
vessel.  The improvement of tissue perfusion could 
promote the functional recovery of viable muscle,  
reduce infarct expansion,  and possibly enhance the 
delivery of blood-borne components.  Bone marrow 















Fig. 4　 Coronary blood ﬂow velocity patterns in a case of microemboli (left) and in a case of capillary obstruction.
In a case of microemboli to coronary resistance vessels,  coronary ﬂow velocity falls during the cardiac cycle.  In a case of capillary 
destruction,  the myocardial blood volume decreases signiﬁcantly,  and thus coronary ﬂow rapidly fulﬁlls the unstressed volume of coronary 
microcirculation to cause rapid deceleration of diastolic ﬂow velocity.  Due to the obstruction of capillaries and venules,  an increase in 
systolic myocardial stress causes the reverse ﬂow,  called systolic ﬂow reversal.
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components contain endothelial precursors with pheno-
typic and functional characteristics of embryonic 
hemangioblasts,  andthese can be used to directly 
induce new blood vessel formation in the infarct bed 
(vasculogenesis) and the proliferation of pre-existing 
vasculature (angiogenesis) after experimental myocar-
dial infarction [15].  Neovascularization of ischemic 
myocardium by human bone marrow-derived angio-
blasts prevents cardiomyocyte apoptosis,  reduces 
remodeling,  and improves cardiac function.
　 Treatment of microemboli. Promising 
adjunctive therapies to reduce microemboli include 
intensive anti-platelet therapy with aspirin and clopi-
dogrel,  platelet glycoprotein IIb/IIIa receptor inhibi-
tors,  coronary vasodilators,  and devices to protect 
against embolization.  Thrombolytic agents seem not to 
improve microvascular function.
　 Aggressive treatment of platelet microemblism with 
glycoprotein IIb/IIIa receptor inhibitors has yielded 
encouraging results.  The Abciximab before Direct 
Angioplasty and Stenting in Myocardial Infarction 
Regarding Acute and Long-Term Follow-up 
(ADMIRAL) trial [16] provided preliminary evidence 
that intravenous abciximab is associated with a highin-
cidence of TIMI-3 ﬂow and with an 80ｵ reduction in 
adverse cardiac events compared with control among 
acute MI patients undergoing primary PCI.  However,  
it remains unknown whether the improvement in coro-
nary ﬂow is mediated by the inhibition of platelet 
aggregation or by faster establishment of epicardial 
artery recanalization.  
　 A more direct method to reduce the thrombus or 
plaque burden is to retrieve embolic materials with 
catheter-based devices.  Some devices directly aspirate 
thrombus and plaque contents at the occlusion site,  
and others are distal protection devices designed to 
trap embolic materials.  These systems eﬀectively 
retrieve embolic debris in most patients with acute MI 
undergoing emergent PCI.  Nonetheless,  distal embo-
lic protection has failed to show improved microvascu-
lar ﬂow,  greater reperfusion success,  reduced infarct 
size,  or enhanced event-free survival [17,  18].  The 
patients in whom these devices are to be used should,  
therefore,  be selected carefully.  Identiﬁcation of 
ruptured plaque by intravascular angioscopy might be 
useful for identifying patients who could respond to 
distal protection [19].
　 Treatment of capillary dysfunction. If 
pharmacologic intervention could protect myocytes and 
the microvasculature against ischemic injury,  reperfu-
sion injury,  or both,  post-ischemic microvascular ﬂow 
would be augmented and functional and clinical out-
comes improved.  Adenosine yields beneﬁts beyond 
simple vasodilation that make it a potential therapy to 
achieve this goal.  Adenosine lowers neutrophil counts 
in infarct zones,  maintains endothelial integrity and 
may exert a cardioprotective eﬀect that is related to 
ischemic preconditioning.  In patients with acute MI,  
intracoronary administration of 24ﾝ48㎍ adenosine is 
well tolerated and improves microvascular and ven-
tricular function in the infarct zone,  leading to an 
improved clinical course after PCI [20].  Intravenous 
administration of adenosine,  however,  is not powerful 
enough to reduce infarct size.  The AMISTAD II trial 
assessed clinical outcomes and infarct size in 21,118 
patients with ST-segment elevation MI undergoing 
reperfusion therapy,  with adenosine as an adjunct 
therapy [21].  The clinical outcomes were not signiﬁ-
cantly improved with adenosine,  although infarct size 
was reduced with a high-dose infusion (70㎍ ㎏－1 min－1).  
Nicorandil is a hybrid between amitochondrial potas-
sium-channel opener and NO,  and has showed promis-
ing results in patients with acute MI when given 
before reperfusion.  This drug reduces preload and 
afterload,  dilates coronary resistance vessels,  reduces 
Ca2＋ overload of myocytes,  and attenuates neutrophil 
activation.  Since the mitochondrial potassium channel 
is an end-eﬀector of the ischemic preconditioning 
pathway,  nicorandil could protect myocardium against 
ischemic injury.  Studies have demonstrated that among 
reperfused patients who received intravenously admin-
istered nicorandil,  infarct size was reduced and clini-
cal outcome improved [22,  23].  An associated 
improvement in microvascular perfusion was observed 
in the nicorandil treatment group.  
　 The use of vasodilators,  including nitrates,  vera-
pamil,  papaverine,  nicardipine,  and sodium nitrop-
russide may also have a role in improving post-isch-
emic microvascular function.  Intracoronary 
nitroprusside or verapamil was associated with a sig-
niﬁcant improvement in coronary ﬂow,  with an 
increase in TIMI ﬂow grade [24,  25].  Intracoronary 
verapamil was associated with better functional recov-
ery in wall motion abnormalities.  These strategies are 
not formally approved for treating no-reﬂow.  In cases 
of TIMI-2 ﬂow after PCI,  we should attempt this 
166 Acta Med.  Okayama　Vol.  63,  No.  4Ito
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strategy to restore coronary blood ﬂow,  which is 
essential for improved left ventricular function and 
better cardiac outcomes.  
　 Sodium‒hydrogen pump inhibitors have the poten-
tial to reduce reperfusion injury by attenuating intra-
cellular Ca2＋overload.  In an experimental study,  the 
use of such an agent improved microvascular function 
and myocardial blood ﬂow,  and reduced infarct size 
[26].  Large-scale,  multicenter trials did not,  how-
ever,  show any beneﬁt of cariporide or eniporide on 
functional and clinical outcomes in patients with a wide 
range of ischemic risk [27,  28].  Other adjunctive 
agents,  including monoclonal antibodies to leukocytes,  
complement receptor inhibitors,  adhesion molecule 
antibodies,  endothelin-A selective antagonists,  and 
erythropoietin,  might have potential therapeutic roles.  
Double-blind,  randomized multicenter trials should be 
conducted to assess the potential of these agents to 
treat the no-reﬂow phenomenon or to determine the 
appropriate dosage.
　 Catheter-based techniques can exert cardio-protec-
tive eﬀects.  Experimental studies have demonstrated 
that multiple,  short induced coronary occlusions 
immediately after sustained myocardial ischemia are 
associated with reduced MI size compared with sudden 
reperfusion [29].  This cardio-protective intervention 
is called post-conditioning.  The mechanism of protec-
tion involves the activation of extracellular-signal-
regulated kinase,  production of nitric oxide,  opening 
of mitochondrial potassium channels,  and inhibition of 
the opening of the mitochondrial permeability transi-
tion pore.  A similar approach could be applied in 
cardiac catheterization laboratories to protect reper-
fused myocardium after primary angioplasty in 
patients with acute MI.  Staat et al.  [30] performed 
postconditioning during PCI for acute MI in humans,  
starting within 1 min of reﬂow,  and achieved by inﬂat-
ing an angioplasty balloon for 1 min followed by deﬂa-
tion for 1 min 4 times.  Improvements were seen in 
myocardial perfusion and functional outcomes com-
pared with those in patients who did not undergo post-
conditioning.  This catheter-based technique may be 
clinically applicable in PCI,  CABG,  organ transplan-
tation,  and peripheral revascularization where reper-
fusion injury is expressed.  
Conclusions
　 The no-reﬂow phenomenon occurs in a notable 
proportion of patients with acute MI,  despite aggres-
sive reperfusion therapy,  and is associated with a poor 
prognosis.  To stratify risk among acute MI patients,  
it is useful to look beyond epicardial artery patency 
and to assess microvascular perfusion.  The identiﬁca-
tion of a mechanism of microvascular dysfunction is the 
key to deﬁning speciﬁc therapeutic strategies for 
reperfusion.  To accelerate the development of new 
reperfusion regimens,  an integrated approach that 
incorporates multiple eﬃcacy variables to assess the 
success or failure of tissue perfusion could be 
required.  
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